The FDA said over 100 preliminary reports of a fungal infection had been reported to 17 different CDC Prevention centers. Although the FDA said it was not aware of a direct link between the Fusarium fungus and any specific product, in 26 cases thus far, patients used Bausch & Lomb's ReNu MoistureLoc solution.
The halt in shipments was another low blow for Bausch & Lomb, which said last month it was delaying issuing its 2005 annual report amid some accounting mishaps.
The company's shares tapped a new 52-week low on Monday, even after a bullish story on the firm popped up in this past weekend's Barron's. Barron's was right in thinking that investors may be over-reacting to BOL's fungus-related woes, but they forgot to mention that the overall growth picture at BOL looks bleak.
BOL 1-yr Chart
Aside: Did you know that Seeking Alpha now publishes a one-page recap of Jim Cramer's Mad Money TV show, Lightning Round, Radio program and Stop Trading?